Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%.
Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the same period base, such as retail pharmacies, POCT, etc. Looking ahead to the full year of 2024, the high growth direction in the first quarter is representative. The growth trend is expected to continue, and the pharmaceutical industry is still showing structural growth. In the long run, with a combination of multiple factors such as the application of new technology, new breakthroughs in treatment technology, and the shift driven by China's innovation model, the Chinese pharmaceutical industry will always find the direction of continuous breakthroughs. The bank believes that there is no need to be too pessimistic about pharmaceuticals. After the 2021-2023 adjustment and transition, the industry also continues to accumulate new changes, such as sugar reduction and weight loss, autoimmune diseases, AI medicine, and brain-computer interfaces, which are expected to become an important growth direction in the future.
Fangzheng Securities said that against the backdrop of frequent medical reform policies, normalization of collection, and continued expansion of the OTC market, the bank believes that branded OTC companies with steady performance, high dividend rates, and both product+brand+channel have a high investment value.